Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis

Expert Opinion on Drug Safety

Volumn 12, Issue 6, 2013, Pages 801-804

  Murdaca, Giuseppe ^a   Spanò, Francesca ^a   Puppo, Francesco ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Leflunomide; Opportunistic infections; Rheumatoid arthritis; TNF inhibitors

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG USE; HUMAN; LATENT TUBERCULOSIS; OPPORTUNISTIC INFECTION; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS; ISOXAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84886626779     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.823947     Document Type: Review

References (36)

1. Fox RI, Herrmann ML, Frangou CG, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 1999;93(3):198-208
2. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999;159(21):2542-50
3. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999;353(9149):259-66
4. Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford ;39(6):655-65
5. Kremer J, Genovese M, Cannon GW, et al. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: Open-label extension of a randomized, double-blind, placebo controlled trial. J Rheumatol 2004;31(8):1521-31
6. Golicki D, Newada M, Lis J, et al. Leflunomide in monotherapy of rheumatoid arthritis: Meta-analysis of randomized trials. Pol Arch Med Wewn 2012;122(1-2):22-32
7. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69(6):964-75
8. Londono J, Santos AM, Santos PI, et al. Therapeutic efficacy and safety of methotrexate + leflunomide in Colombian patients with active rheumatoid arthritis refractory to conventional treatment. Rev Bras Reumatol 2012;52(6):837-45
9. Kellner H, Bornholdt K, Hein G. Leflunomide in the treatment of patients with early rheumatoid arthritis-results of a prospective non-interventional study. Clin Rheumatol 2010;29(8):913-20
10. Bergner R, Peters L, Schmitt V, L€offler C. Leflunomide in dialysis patients with rheumatoid arthritis-A pharmacokinetic study. Clin Rheumatol 2013;32(2):267-70
11. Yoo HG, Yu HM, Jun JB, et al. Risk factors of severe infections in patients with rheumatoid arthritis treated with leflunomide. Mod Rheumatol 2012; In press
12. Lee SW, Park HJ, Kim BK, et al. Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate. Arthritis Res Ther 2012;14(5):R232
13. Murdaca G, Colombo BM, Puppo F. Anti-TNF-alpha inhibitors: A new therapeutic approach for inflammatory immune-mediated diseases: An update upon efficacy and adverse events. Int J Immunopathol Pharmacol 2009;22(3):557-65
14. Murdaca G, Colombo BM, Cagnati P, et al. Update upon efficacy and safety of TNF-alpha inhibitors. Expert Opin Drug Saf 2012;11(1):1-5
15. Murdaca G, Colombo BM, Puppo F. Emerging biological drugs: A new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events. Autoimmun Rev 2011;11(1):56-60
16. Murdaca G, Colombo BM, Puppo F. Adalimumab for the treatment of immune-mediated diseases: An update on old and recent indications. Drugs Today (Barc) 2011;47(4):277-88
17. Murdaca G, Colombo BM, Barabino G, et al. Anti-tumor necrosis factor-alpha treatment with infliximab for disseminated granuloma annulare. Am J Clin Dermatol 2010;11(6):437-9
18. Puppo F, Murdaca G, Ghio M, Indiveri F. Emerging biologic drugs for the treatment of rheumatoid arthritis. Autoimmun Rev 2005;4(8):537-41
19. Murdaca G, Spanò F, Puppo F. Selective TNF-alpha inhibitor-induced injection site reactions. Expert Opin Drug Saf 2013;12(2):187-93
20. Kalden JR, Nu?sslein HG, Wollenhaupt J, et al. Combination treatment with infliximab and leflunomide in patients with active rheumatoid arthritis: Safety and efficacy in an open-label clinical trial. Clin Exp Rheumatol 2008;26(5):834-40
21. Kiely PD, Johnson DM. Infliximab and leflunomide combination therapy in rheumatoid arthritis: An open-label study. Rheumatology (Oxford ;41(6):631-7
22. Sokolove J, Strand V, Greenberg JD, et al. CORRONA Investigators. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis 2010;69(9):1612-17
23. Benucci M, Saviola G, Baiardi P, et al. Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis. Int J Immunopathol Pharmacol 2011;24(1):269-74
24. Minoretti P, Bruno A, Di Vito C, Emanuele E. Leflunomide as an antiatherogenic drug. Med Hypotheses 2007;68(5):1175-6
25. Murdaca G, Spanò F, Cagnati P, Puppo F. Free radicals and endothelial dysfunction: Potential positive effects of TNF-alpha inhibitors. Redox Rep 2013; In press
26. Murdaca G, Spanò F, Miglino M, Puppo F. Effects of TNF-alpha inhibitors upon the mechanisms of action of VEGF. Immunotherapy 2013;5(2):113-15
27. Ciprandi G, Murdaca G, Colombo BM, et al. Serum vascular endothelial growth factor in allergic rhinitis and systemic lupus erythematosus. Hum Immunol 2008;69(8):510-12
28. Ciprandi G, Colombo BM, Murdaca G, De Amici M. Serum vascular endothelial growth factor and sublingual immunotherapy. Allergy 2008;63(7):945-6
29. Szekanecz Z, Kerekes G, Soltész P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol 2009;5(12):677-84
30. Colombo BM, Cacciapaglia F, Puntoni M, et al. Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: Role of vascular endothelial growth factor (VEGATS Study). Autoimmun Rev 2009;8(4):309-15
31. Colombo BM, Murdaca G, Caiti M, et al. Intima-media thickness: A marker of accelerated atherosclerosis in women with systemic lupus erythematosus. Ann N Y Acad Sci 2007;1108:121-6
32. Murdaca G, Colombo BM, Cagnati P, et al. Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis 2012;224(2):309-17
33. Takemura S, Braun A, Crowson C, et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001;167:1072-80
34. Murdaca G, Colombo BM, Puppo F. The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases. Intern Emerg Med 2011;6(6):487-95
35. Chiang EY, Kolumam GA, Yu X, et al. Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med 2009;15(7):766-73
36. Murdaca G, Colombo BM, Contini P, Puppo F. Determination of lymphotoxin-alpha levels in patients with psoriatic arthritis undergoing etanercept treatment. J Interferon Cytokine Res 2012;32(6):277-9